2 enrolling by invitation, 1 completed. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Enrolling by invitation 2, Completed 1 |
| Phase 1 | 2 | Completed 1, Enrolling by invitation 1 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Nasus Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis FMXIN002 single dose, Epinephrine autoinjector single dose, FMXIN002 single dose + NAC - Anaphylaxis, Allergy | Phase 1 / Phase 2 | Enrolling by invitation | Nasus Pharma | 50 | 2025-11-03 | 2025-11-14 |
| FMXIN002 in Patients at Risk of Anaphylaxis Epinephrine 4mg nasal powder spray, Adrenalin 0.5mg Injectable Product - Anaphylaxis Food | Phase 2 / Phase 3 | Enrolling by invitation | Nasus Pharma | 30 | 2025-06-12 | 2025-07-01 |
| Comparative Bioavailability of Intranasal Epinephrine A: Epinephrine injection, B: FMXIN002 3.6mg, C: FMXIN002 4.0mg - Anaphylaxis, Anaphylactic Reaction | Phase 1 / Phase 2 | Completed | Nasus Pharma | 12 | 2023-08-22 | 2025-06-18 |
Anaphylaxis (2) · Hypersensitivity (1)
Epinephrine (3) · Injections (1)
Israel (2) · Canada (1)
Arnon Elizur, Prof. (1) · Mark L Freedman, MD, FRCPC (1) · Yoseph Caraco, Professor (1)